Details(active tab)Additional Information Details Basic Details Date Thursday, January 17, 2019 Medical Product canagliflozin dapagliflozin empagliflozin sitagliptin sodium-glucose cotransporter-2 (SGLT-2) inhibitor Health Outcome(s) diabetic ketoacidosis Meeting Details View the Advisory Committee Meeting Materials here Additional Information Related Link(s) Sentinel Drug Study: Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors & Diabetic Ketoacidosis (DKA) and Use in Type 1 Diabetes Mellitus (T1DM) Related Assessment(s) SGLT-2 Inhibitor Use and Incidence of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus